Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740274 | 1.00 | PTGDR2 (0.45) | PTGDR2TMEM97SIGMAR1GRM5S1PR5 | |
| SCHEMBL20293305 | 0.92 | PARP1 (0.40) | PTGDR2TMEM97SIGMAR1GRM5S1PR5 | |
| SCHEMBL30145264 | 0.92 | PARP1 (0.40) | PTGDR2TMEM97SIGMAR1GRM5S1PR5 | |
| SCHEMBL505382 | 0.81 | PPARA (0.50) | PTGDR2TMEM97SIGMAR1GRM5S1PR5 | |
| SCHEMBL17377166 | 0.81 | DHFR (0.49) | PTGDR2TMEM97SIGMAR1GRM5KDR | |
| SCHEMBL504679 | 0.79 | S1PR5 (0.52) | TMEM97SIGMAR1GRM5S1PR5KDR | |
| SCHEMBL504584 | 0.79 | DHFR (0.44) | PTGDR2TMEM97SIGMAR1GRM5S1PR5 | |
| SCHEMBL505215 | 0.78 | GRM5 (0.56) | GRM5S1PR5DHFR | |
| SCHEMBL504656 | 0.78 | DHFR (0.46) | PTGDR2TMEM97SIGMAR1GRM5KDR | |
| SCHEMBL10250503 | 0.78 | DHFR (0.48) | PTGDR2TMEM97SIGMAR1GRM5S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-01-07 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3558985-B1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PTGDR2 143/4885TMEM97 3917/4885SIGMAR1 2957/4885 |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PTGDR2 143/4885TMEM97 3917/4885SIGMAR1 2957/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PTGDR2 143/4885TMEM97 3917/4885SIGMAR1 2957/4885 |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | PTGDR2 299/4885TMEM97 4129/4885SIGMAR1 3921/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PTGDR2 143/4885TMEM97 3917/4885SIGMAR1 2957/4885 |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | IL2, TSLP, CD74 | PTGDR2 306/4885TMEM97 4357/4885SIGMAR1 4143/4885 |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PTGDR2 143/4885TMEM97 3917/4885SIGMAR1 2957/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PTGDR2 143/4885TMEM97 3917/4885SIGMAR1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.